Viral hepatitis is a leading cause of morbidity and mortality worldwide, but has long been
neglected by national and international policymakers. Recent modelling studies suggest that …

Abstract Background HIV, Hepatitis C virus (HCV), and hepatitis B virus (HBV) are
substantial public health threats in the region of Central Asia and the Caucasus, where the …

Objective We assessed the impact of direct-acting antiviral (DAA) therapy on liver fibrosis
regression measured by transient elastography (TE) in patients with chronic hepatitis C virus …

Abstract Background The World Health Organization (WHO) has developed a global health
strategy to eliminate viral hepatitis. We project the treatment and prevention requirements to …

Introduction In the light of the advances in HCV antiviral therapy, global control of HCV
infection becomes feasible but depends on the capacity of countries to identify infected …

The development of vaccines that protect against persistent hepatitis C virus (HCV) infection
remain a public health priority. The broad use of highly effective direct-acting antivirals …

The simplification of current hepatitis C diagnostic algorithms and the emergence of digital
diagnostic devices will be very crucial to achieving the WHO's set goals of hepatitis C …

Direct-acting antivirals (DAAs) have dramatically changed the landscape of hepatitis C
treatment and prevention. The World Health Organization has called for the elimination of …

Background & Aims Georgia, with a high prevalence of HCV infection, launched the world's
first national hepatitis C elimination program in April 2015. A key strategy is the identification …

Abstract Background The country of Georgia launched the world's first Hepatitis C Virus
(HCV) Elimination Program in 2015 and set a 90% prevalence reduction goal for 2020. We …